Jupiter Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARQT
Jupiter Asset Management's ARQT Position: Q3 2026 in Review
Jupiter Asset Management increased its Arcutis Biotherapeutics (ARQT) stake by 250% in Q3 2026, buying an estimated $13.3M and bringing the position to 709,620 shares worth $18.8M. The position accounts for 0.09% of the portfolio, ranked #239.
Jupiter Asset Management first reported a position in ARQT in Q2 2025 and has held it in 6 quarters since. 212 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.
- Jupiter Asset Management held 709,620 shares of Arcutis Biotherapeutics worth $18.8M as of Q3 2026.
- Jupiter Asset Management bought 507,105 Arcutis Biotherapeutics shares in Q3 2026, an estimated $13.3M.
- Arcutis Biotherapeutics made up 0.09% of Jupiter Asset Management's portfolio in Q3 2026, its #239 holding.
- Jupiter Asset Management first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 6 quarters since.
- 212 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.
Based on Jupiter Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.